Tandem Diabetes reports Q3 EPS (35c), consensus (40c)

Reports Q3 revenue $244.0M, consensus $223.7M. The company: “Grew worldwide pump shipments by more than 25 percent compared to third quarter 2023. Achieved year-over-year growth in new pump starts in the United States, including growth in new customers starting from multiple daily injections. Demonstrated positive Adjusted EBITDA and a return to positive free cash flow.” “The third quarter marked a milestone achievement for Tandem Diabetes (TNDM) Care as we delivered the highest quarterly sales in our Company’s history, both in the U.S. and internationally,” said John Sheridan, president and chief executive officer. “This performance, coupled with our strong operational execution, positions us well to achieve our remaining goals for 2024 and beyond, as we further our mission to improve the lives of people with diabetes.”